Pseudomonas Aeruginosa Infection Treatment Market (Medication Type: Monotherapy and Combination Therapy; Drug Type: Aminoglycoside, Cephalosporin, Carbapenem, Monobactam and Others)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Pseudomonas Aeruginosa Infection Treatment market size was estimated at USD 1.7 billion in 2021 and is expected to surpass around USD 2.9 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 6.9% during the forecast period 2022 to 2030.

Pseudomonas Aeruginosa Infection Treatment Market Introduction

Pseudomonas aeruginosa is a type of bacteria that can cause infections in individuals after they undergo a surgery. Infection can occur in the blood, lungs, or other parts of the body. Pseudomonas aeruginosa infection treatment includes various medications, therapies, and procedures that can reduce the infection caused to an individual. Pseudomonas aeruginosa infection is generally treated through antibiotics and other drugs.

The global pseudomonas aeruginosa infection treatment market size is estimated to increase significantly during the forecast period owing to an increase in prevalence of pseudomonas aeruginosa, surge in awareness about the disease, adoption of expansion strategies, and robust pipeline of new therapeutic in clinical trials

Report Scope of the Pseudomonas Aeruginosa Infection Treatment Market

 Increase in Incidence of Nosocomial Infections to Boost Market

Rise in prevalence of nosocomial infections associated with P. aeruginosa, such as pneumonia, urinary tract infections (UTI), cystic fibrosis, and blood stream infections, is likely to augment the global pseudomonas aeruginosa infection treatment market during the forecast period.

Increase in incidence of bacterial infections, i.e., Pseudomonas aeruginosa infections, in intensive care with no effective treatment is projected to drive the demand for newer antibacterial drugs and antibiotics for pseudomonas aeruginosa infection treatment.

According to Centers for Disease Control and Prevention (CDC) estimates, around 51,000 health care-associated P. aeruginosa infections occur in the U.S. each year. More than 6,000 (13%) of these are multidrug-resistant, with roughly 400 deaths per year attributed to these infections.

Rapid Rise in Antibacterial Drug Resistance to Augment Market

Antibacterial drug resistance is growing rapidly across the world, as it is in the nature of bacteria to develop resistance. This has generated the urgent need of new research and innovation in the antibacterial field.

According to U.S. Centers for Disease Control and Prevention (CDC) estimates, antibacterial resistance is responsible for over 2 million infections and 23,000 deaths in the U.S. each year and an estimated 25,000 deaths due to antibacterial-resistant infections in Europe. Hence, demand for newer broad spectrum antibacterial drugs is rising. There is always a need of antibacterial drugs for the treatment of children with fatal sepsis and severe pneumonia.

High Demand for Combination Therapy for Pseudomonas Aeruginosa Infection Treatment

In terms of medication type, the global pseudomonas aeruginosa infection treatment market has been bifurcated into monotherapy and combination therapy. The combination therapy segment held around 74% of the global pseudomonas aeruginosa infection treatment market share in 2021. The segment is likely to maintain the status quo during the forecast period. The segment growth is due to increased drug resistance in monotherapy, which has resulted in a rise in the demand for combination therapy for the treatment of P. aeruginosa infection.

Combination therapy helps increase compliance, synergy, and efficacy, and reduce side-effects and cost. These factors are projected to boost the combination therapy segment. Additionally, rise in demand for combination therapy for treatment of pseudomonas aeruginosa infection is attributed to rapid onset of action, high bioavailability rate, cost saving, and high efficiency.

Focus of Major Pharmaceutical Companies on Development of New Class of Cephalosporin Drugs

In terms of drug type, the global pseudomonas aeruginosa infection treatment market has been classified into aminoglycoside, cephalosporin, carbapenem, monobactam, and others.

The cephalosporin segment held a major share of around 40% in 2021. It is estimated to maintain the status quo during the forecast period. Expansion of the segment can be attributed to the focus of major pharmaceutical companies on the development of new class of cephalosporin for the treatment of various P. aeruginosa infections. This is expected to fuel the growth of the cephalosporin segment.

New cephalosporin (fifth-generation) was developed for the treatment of gram negative bacteria such as P. aeruginosa, methicillin-resistant staphylococcus aureus, and others. Launch of new cephalosporin class of drugs is likely to boost the segment.

Intravenous is Preferred Route of Administration for Pseudomonas Aeruginosa Infection Treatment

In terms of route of administration, the global pseudomonas aeruginosa infection treatment market has been split into nasal, oral, and intravenous.

The intravenous segment held a major share of around 40% in 2021. The segment is projected to grow and maintain its position during the forecast period due to the availability of the drugs for intravenous route, high accuracy in dosing, and rapid onset of action as compared to other routes.

Most physicians prefer intravenous route for administration of drugs because the entire administered dose reaches the systemic circulation, immediately, resulting in rapid onset of action against bacteria. This factor is expected to augment the segment.

Well-developed Infrastructure and Growth in Adoption of New Products Augmenting Hospital Pharmacies Segment

In terms of distribution channel, the global pseudomonas aeruginosa infection treatment market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies.

The hospital pharmacies segment held a major share of around 46% of the global market in 2021. The segment is projected to grow during the forecast period due to an increase in the number of multi-specialty hospitals in developing countries. Additionally, well-developed infrastructure and increase in adoption of new products by hospital pharmacies are likely to propel the segment during the forecast period.

Regional Outlook of Global Pseudomonas Aeruginosa Infection Treatment Market

Europe held a notable share of around 31% of the global pseudomonas aeruginosa infection treatment market, in terms of volume, in 2021. Europe is anticipated to account for a leading share of the global market during the forecast period, owing to an increase in the number of patients suffering from pseudomonas aeruginosa infection in the region.

North America held around 30% share of the global pseudomonas aeruginosa infection treatment market, in terms of value, in 2021. The market in the region grew at a notable growth rate due to a rise in aging population, highly structured health care industry, and availability of well-defined reimbursement policies from public and private health insurance firms, which are fueling the treatments for pseudomonas aeruginosa infection.

Middle East & Africa held a larger share of the global market as compared to that held by Latin America; however, the market in Latin America is estimated to rise at a higher growth rate as compared to the market in Middle East & Africa.

Analysis of Key Players in Global Pseudomonas Aeruginosa Infection Treatment Market

The pseudomonas aeruginosa infection treatment market report concludes with the company profiles section, which includes key information about major players in the global pseudomonas aeruginosa infection treatment market. The pseudomonas aeruginosa infection treatment market companies include ALLERGAN, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Lupin Pharmaceuticals, Inc., AstraZeneca, Merck & Co., Inc., Bristol-Myers Squibb Co. and Janssen Pharmaceuticals, Inc.

Key Developments in Global Pseudomonas Aeruginosa Infection Treatment Market

• In May 2021, Teva Pharmaceutical Industries Ltd. introduced erythromycin tablets with a strength of 250 mg and 500 mg. Erythromycin tablets are prescribed to treat various bacterial infections as well as rheumatic fever in patients who have an allergy to penicillin.
• In February 2019, Merck announced that the FDA accepted for Priority Review a supplemental NDA for Zerbaxa to treat adult patients with nosocomial pneumonia, including ventilator-associated pneumonia, caused by certain susceptible Gram-negative microorganisms.

Some of the prominent players in the Pseudomonas Aeruginosa Infection Treatment Market include:

• ALLERGAN
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Lupin Pharmaceuticals, Inc.
• AstraZeneca
• Merck & Co., Inc.
• Bristol-Myers Squibb Co.
• Janssen Pharmaceuticals, Inc.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Pseudomonas Aeruginosa Infection Treatment market

• Medication Type
• Monotherapy
• Combination Therapy
• Drug Type
• Aminoglycoside
• Cephalosporin
• Carbapenem
• Monobactam
• Others
• Route of Administration
• Nasal
• Oral
• Intravenous
• Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Pseudomonas Aeruginosa Infection Treatment industry analysis from 2022 to 2030 to identify the prevailing Pseudomonas Aeruginosa Infection Treatment industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Pseudomonas Aeruginosa Infection Treatment industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Pseudomonas Aeruginosa Infection Treatment industry trends, key players, market segments, application areas, and market growth strategies.